Publications by authors named "James Demarest"

Claim this Profile
S
Small molecule direct-acting antivirals for treatment of mpox.
E Randall Lanier, Richard L Mackman, Lee Ruggiero, James F Demarest, John C Pottage

Antiviral Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness.
Ruxandra Draghia-Akli, Nina M Hill, Bruce Altevogt, Kenneth Bradley, Kelly Chibale, James F Demarest

Clin Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral target compound profile for pandemic preparedness.
James F Demarest, Ruxandra Draghia-Akli, Tomas Cihlar, Kenneth Bradley, John A T Young

Nat Rev Drug Discov· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
James F Demarest, Maryline Kienle, RuthMabel Boytz, Mary Ayres, Eun Jung Kim

Antiviral Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Galidesivir in a Hamster Model of SARS-CoV-2.
Ray Taylor, Richard Bowen, James F Demarest, Michael DeSpirito, Airn Hartwig

Viruses· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
Justin G Julander, James F Demarest, Ray Taylor, Brian B Gowen, Dennis M Walling

Antiviral Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
Vani Vannappagari, Leigh Ragone, Cassidy Henegar, Jean van Wyk, Dannae Brown, James Demarest

Antivir Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Marta Boffito, Laura Waters, Pedro Cahn, Roger Paredes, Justin Koteff, James Demarest

AIDS Res Hum Retroviruses· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.
Jayvant Heera, Srinivas R Valluri, Charles Craig, Annie Fang, Neal Thomas, James Demarest

New Microbiol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
James Demarest, Mark Underwood, Marty St Clair, David Dorey, Dannae Brown

AIDS Res Hum Retroviruses· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.
Jayvant Heera, Srinivas Valluri, Charles Craig, Annie Fang, Neal Thomas, James Demarest

J Int AIDS Soc· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
Elna van der Ryst, Jayvant Heera, James Demarest, Charles Knirsch

Ann N Y Acad Sci· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliable genotypic tropism tests for the major HIV-1 subtypes.
Kieran Cashin, Lachlan R Gray, Katherine L Harvey, Danielle Perez-Bercoff, Guinevere Q Lee, James F Demarest

Sci Rep· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Luke C Swenson, Celia K S Chui, Chanson J Brumme, Dennison Chan, Conan K Woods, James F Demarest

Antimicrob Agents Chemother· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.
Guinevere Q Lee, P Richard Harrigan, Winnie Dong, Art F Y Poon, Jayvant Heera, James Demarest

AIDS Res Hum Retroviruses· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Luke C Swenson, Winnie W Y Dong, Theresa Mo, James Demarest, Doug Chapman

Clin Infect Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.
Simon Portsmouth, Srinivas Rao Valluri, Martin Däumer, Bernhard Thiele, Hernan Valdez, James Demarest

Antiviral Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
Jennifer M Pfaff, Craig B Wilen, Jessamina E Harrison, James F Demarest, Benhur Lee

J Virol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
John C Tilton, Heather Amrine-Madsen, John L Miamidian, Kathryn M Kitrinos, Jennifer Pfaff, James F Demarest

AIDS Res Hum Retroviruses· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
James F Demarest, Heather Amrine-Madsen, David M Irlbeck, Kathryn M Kitrinos,

Antimicrob Agents Chemother· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.
Kathryn M Kitrinos, Heather Amrine-Madsen, David M Irlbeck, J Michael Word, James F Demarest

Antimicrob Agents Chemother· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
James F Demarest, Sara S Sparks, Kathleen Schell, Shiro Shibayama, Charlene B McDanal

J Clin Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
David M Irlbeck, Heather Amrine-Madsen, Kathryn M Kitrinos, Celia C Labranche, James F Demarest

AIDS· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
Jacob Lalezari, Melanie Thompson, Priny Kumar, Peter Piliero, Richard Davey, James Demarest

AIDS· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
Annika C Karlsson, Steven G Deeks, Jason D Barbour, Brandon D Heiken, Sophie R Younger, James F Demarest

J Virol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis